Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study

Talha Badar; Ravi Narra; Alice S Mims; Michael G Heckman; Rory M Shallis; Sheikh Fahad; Cameron Hunter; Vamsi Kota; Tamer Adel Othman; Brian Jonas; Shreya Desai; Guilherme Sacchi de Camargo Correia; Anand Patel; Adam S DuVall; Neil Palmisiano; Emily Curran; Zulfa Omer; Anjali Advani; Ehab Atallah; Mark Litzow

doi:10.1002/ajh.27475

Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study

Am J Hematol. 2024 Dec;99(12):2388-2391. doi: 10.1002/ajh.27475. Epub 2024 Sep 10.

Authors

Talha Badar¹, Ravi Narra², Alice S Mims³, Michael G Heckman⁴, Rory M Shallis⁵, Sheikh Fahad⁴, Cameron Hunter⁵, Vamsi Kota⁶, Tamer Adel Othman⁷, Brian Jonas⁷, Shreya Desai⁶, Guilherme Sacchi de Camargo Correia¹, Anand Patel⁸, Adam S DuVall⁸, Neil Palmisiano⁹, Emily Curran¹⁰, Zulfa Omer¹⁰, Anjali Advani¹¹, Ehab Atallah², Mark Litzow¹²

Affiliations

¹ Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, Florida, USA.
² Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
³ Division of Hematology and Oncology, Ohio State University, Columbus, Ohio, USA.
⁴ Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida, USA.
⁵ Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
⁶ Division of Hematology and Oncology, Georgia Cancer Center, Augusta, Georgia, USA.
⁷ Division of Hematology and Oncology, University of California-Davis, Davis, California, USA.
⁸ Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
⁹ Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey, USA.
¹⁰ Department of Medicine, Division of Hematology and Oncology University of Cincinnati, Cincinnati, Ohio, USA.
¹¹ Division of Hematology, Cleveland Clinic, Cleveland, Ohio, USA.
¹² Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 39253997
DOI: 10.1002/ajh.27475

Abstract

Intensive chemotherapy (IC) combination with second- or third-generation TKI improves survival compared to non-IC with first-generation TKI. Allo-HCT was suggestive of improving RFS/OS after propensity score matching and multivariable analysis.

Publication types

Multicenter Study
Letter

MeSH terms

Adolescent
Adult
Aged
Allografts
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Hematopoietic Stem Cell Transplantation*
Humans
Induction Chemotherapy
Male
Middle Aged
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use
Retrospective Studies
Survival Rate
Transplantation, Homologous
Young Adult

Substances

Protein Kinase Inhibitors